Immunotherapy最新文献_第5页

From blood draw to tumor infiltration: therapeutic variations in CAR-macrophage therapy for solid tumors. 从抽血到肿瘤浸润：car -巨噬细胞治疗实体瘤的治疗变化

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-05-01 Epub Date: 2026-06-13 DOI: 10.1080/1750743X.2026.2688710

Mohsen Ghasem Zadeh Soroush, Alieh Mirzaei, Mahan Ranjbar, Mobin Mohammadi, Arman Baghbanzadeh, Shayesteh Kokabi Hamidpour, Seied Asadollah Mousavi, Mostafa Rezaei-Tavirani, Babak Arjmand

{"title":"From blood draw to tumor infiltration: therapeutic variations in CAR-macrophage therapy for solid tumors.","authors":"Mohsen Ghasem Zadeh Soroush, Alieh Mirzaei, Mahan Ranjbar, Mobin Mohammadi, Arman Baghbanzadeh, Shayesteh Kokabi Hamidpour, Seied Asadollah Mousavi, Mostafa Rezaei-Tavirani, Babak Arjmand","doi":"10.1080/1750743X.2026.2688710","DOIUrl":"10.1080/1750743X.2026.2688710","url":null,"abstract":"Introduction: Engineering CAR-macrophages (CAR-Ms) has revolutionized the solid tumors immunotherapy, due to intrinsic anti-tumor capacity, phagocytosis ability, and immunomodulatory effects of macrophages in tumor microenvironment (TME) remodeling.Methodology: A literature review was conducted using databases including PubMed, Google Scholar, and Scopus. The data was extracted using relevant articles published from 1991 to 2026 based on key words such as Chimeric Antigen Receptor Macrophages, CAR-M, Immunotherapy Resistance, Solid Tumors, and Tumor Microenvironment.Areas covered: CAR-Ms originate from different sources, but in turn come with distinct advantages and challenges regarding scalability, polarization capacity, phenotype shift, antigen escape, and functional stability. Genetic engineering techniques are essential to increase CAR-M efficacy. Along with intrinsic engineering, the integration of CAR-Ms with chemotherapy, radiotherapy, immune checkpoint inhibitors, and new methods, such as nanomedicine, enhances antitumor effects by modulating TME barriers and abrogation of immune evasion mechanisms.Expert opinion/commentary: CAR-m therapy is represented as a promising next-generation treatment for solid tumors, due to its strength to overcome the challenges of lymphocyte approaches. However, TME polarization and variability in patient response should be considered to achieve optimal efficacy. Future advancements should improve signaling design, integration of novel immunologic methods, TME modulation, and biomarker-guided patient stratification.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"601-613"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13348915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148251139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Autoimmune encephalitis and axonal polyradiculoneuropathy following therapy with adalimumab and secukinumab: a case report and literature review. 阿达木单抗和secukinumab治疗后的自身免疫性脑炎和轴突多根神经病变：1例报告和文献综述

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-05-01 Epub Date: 2026-06-15 DOI: 10.1080/1750743X.2026.2689844

Juan Sebastián Sánchez León, Eurípedes Gomes de Carvalho Neto, Natana Rangel Ribeiro, Vanessa Dantas de Andrade, Augusto Berton Bettiol, Rafael Coradin, Marlise Ribeiro de Castro

{"title":"Autoimmune encephalitis and axonal polyradiculoneuropathy following therapy with adalimumab and secukinumab: a case report and literature review.","authors":"Juan Sebastián Sánchez León, Eurípedes Gomes de Carvalho Neto, Natana Rangel Ribeiro, Vanessa Dantas de Andrade, Augusto Berton Bettiol, Rafael Coradin, Marlise Ribeiro de Castro","doi":"10.1080/1750743X.2026.2689844","DOIUrl":"10.1080/1750743X.2026.2689844","url":null,"abstract":"Background: Autoimmune encephalitis is a challenging neurological disorder to diagnose, and in recent years the number of reported cases associated with the use of immunotherapy has increased, as has its association with other neurological events, including peripheral nervous system involvement.Case presentation: We report the case of a young woman who presented with polyradiculoneuropathy, manifesting weakness and sensory changes, and who subsequently developed a decreased level of consciousness, aphasia, and right hemiparesis. After extensive investigation, she was diagnosed with autoimmune encephalitis associated with polyradiculoneuropathy and treated with human immunoglobulin and corticosteroids. Due to a partial response, treatment was switched to rituximab, resulting in significant clinical improvement.Conclusions: This case highlights the growing evidence linking biological immunotherapies to autoimmune neurological complications and emphasizes the importance of early recognition and appropriate immunosuppressive treatment.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"559-566"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13348920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in bispecific natural killer cell engagers for cancer immunotherapy. 肿瘤免疫治疗中双特异性自然杀伤细胞接合物的研究进展。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-05-01 Epub Date: 2026-06-19 DOI: 10.1080/1750743X.2026.2688683

Mousa Thalji, Yago Nieto

{"title":"Recent advances in bispecific natural killer cell engagers for cancer immunotherapy.","authors":"Mousa Thalji, Yago Nieto","doi":"10.1080/1750743X.2026.2688683","DOIUrl":"10.1080/1750743X.2026.2688683","url":null,"abstract":"Natural killer (NK) cells are innate cytotoxic lymphocytes capable of eliminating malignant cells independently of major histocompatibility complex (MHC) - restricted antigen recognition. This makes them particularly valuable in tumors that evade adaptive immune surveillance through MHC antigen loss or impaired processing. However, tumor-intrinsic immune evasion mechanisms and suppressive tumor microenvironments frequently impair endogenous NK cell activity, limiting the effectiveness of nontargeted autologous NK cell-based approaches.Bispecific and multispecific NK cell engagers (NKCEs) have emerged as promising immunotherapeutics designed to redirect NK cells toward tumor-associated antigens while delivering potent activating signals. These engineered molecules typically engage activating NK receptors (e.g. CD16a, NKG2D, or NKp46) to promote immune synapse formation and antigen-specific cytotoxicity. Advances in molecular engineering have enabled the development of multispecific platforms that integrate dual tumor antigen targeting, multireceptor activation, and cytokine support - particularly interleukin-15-, to enhance NK cell persistence, expansion, and functional durability.This review highlights progress in NKCE design, preclinical efficacy, and early clinical translation, while addressing safety considerations, mechanisms of resistance, and rational combination strategies, such as with adoptive NK cell therapies and checkpoint inhibitors. Collectively, NKCEs represent versatile, drug-like immunotherapies with the potential to overcome key limitations of monoclonal antibody and T cell - based therapies.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"579-599"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13349013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148277281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis. 抗pd -(L)1联合化疗治疗晚期pd - l1阴性非鳞状非小细胞肺癌：一项系统综述和荟萃分析

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-05-01 Epub Date: 2026-07-03 DOI: 10.1080/1750743X.2026.2689298

Nicolas Peruzzo, Gabriel Lenz, Rafael Alvim Pereira, Oscar Burke, Rui d'Avila, Chinmay Jani, Alexander Drilon, Joshua E Reuss, Paul Leger, Eric K Singhi, Bruna Pellini, Gilberto Lopes

{"title":"Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis.","authors":"Nicolas Peruzzo, Gabriel Lenz, Rafael Alvim Pereira, Oscar Burke, Rui d'Avila, Chinmay Jani, Alexander Drilon, Joshua E Reuss, Paul Leger, Eric K Singhi, Bruna Pellini, Gilberto Lopes","doi":"10.1080/1750743X.2026.2689298","DOIUrl":"10.1080/1750743X.2026.2689298","url":null,"abstract":"Introduction: The benefit of adding anti-PD-(L)1 to chemotherapy in untreated advanced PD-L1-negative nonsquamous non-small cell lung cancer (nsqNSCLC) remains unclear. We conducted a systematic review and meta-analysis to determine whether adding anti-PD-(L)1 therapy to chemotherapy improves outcomes in this population.Materials and methods: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched in September 2025. Eligible studies were phase III randomized clinical trials comparing frontline chemotherapy plus anti-PD-1 or anti-PD-L1 therapy versus chemotherapy with or without placebo in advanced PD-L1-negative nsqNSCLC. Risk of bias was assessed using the Risk of Bias 2 tool. Random-effects models were used to pool hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) and risk ratios (RRs) for overall response rate (ORR).Results: Twelve trials including 2,084 patients were analyzed. Chemotherapy plus anti-PD-(L)1 improved ORR (RR, 1.61; 95% CI, 1.26-2.05; p = 0.0001), PFS (HR, 0.68; 95% CI, 0.60-0.77; p < 0.00001), and OS (HR, 0.81; 95% CI, 0.70-0.94; p = 0.006).Conclusions: Chemotherapy plus anti-PD-(L)1 therapy may be an effective first-line option for advanced PD-L1-negative nsqNSCLC, although the evidence is limited by subgroup-level data and between-study heterogeneity. Protocol registration: PROSPERO, www.crd.york.ac.uk/prospero, identifier 1371679.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"567-578"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13348921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148375582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Time-dependent prognostic impact of distant metastatic sites in small cell lung cancer: a comparative analysis of pre- and post-immunotherapy eras. 小细胞肺癌远处转移部位的时间依赖性预后影响：免疫治疗前和后时代的比较分析。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-05-01 Epub Date: 2026-06-15 DOI: 10.1080/1750743X.2026.2689292

Rashad Ismayilov, Ulkar Ismayilova, Arzu Oguz, Zafer Akcali, Ozden Altundag

{"title":"Time-dependent prognostic impact of distant metastatic sites in small cell lung cancer: a comparative analysis of pre- and post-immunotherapy eras.","authors":"Rashad Ismayilov, Ulkar Ismayilova, Arzu Oguz, Zafer Akcali, Ozden Altundag","doi":"10.1080/1750743X.2026.2689292","DOIUrl":"10.1080/1750743X.2026.2689292","url":null,"abstract":"Aims: To investigate whether the prognostic impact of distant metastatic sites in extensive-stage small cell lung cancer (ES-SCLC) has changed between the pre-immunotherapy and immunotherapy eras.Materials and methods: We analyzed 43,279 metastatic SCLC patients from the SEER database, comparing the pre-immune checkpoint inhibitor (ICI) era (2010-2018) with the ICI era (2019-2022). Overall survival (OS) was assessed using multivariable Cox models. A novel time-dependent area under the curve (AUC) analysis evaluated the dynamic prognostic performance of metastatic sites up to 36 months.Results: Liver metastasis was the most prevalent site (46.3%) and the strongest independent adverse prognostic factor in both the pre-ICI and ICI eras (Mean AUC: 0.626 vs. 0.621, respectively). Notably, the prognostic impact of brain metastasis was neutralized in the ICI era (mean AUC dropping from 0.507 to 0.482), suggesting improved intracranial control. Bone metastasis showed limited prognostic discrimination without concurrent liver involvement.Conclusions: The prognostic landscape of metastatic SCLC has evolved significantly in the immunotherapy era. Liver metastasis persists as the dominant negative factor, whereas the adverse prognostic impact of brain involvement is significantly diminished. These findings underscore the need for organ-specific prognostic stratification in modern SCLC management.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"537-545"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13348909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148251196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Refining adjuvant therapy options in patients with stage II melanoma. 改进II期黑色素瘤患者的辅助治疗方案。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-05-01 Epub Date: 2026-06-12 DOI: 10.1080/1750743X.2026.2688694

Bryant Morocho, Sasha Lightfoot, Ponnandai Somasundar, Steve Kwon

{"title":"Refining adjuvant therapy options in patients with stage II melanoma.","authors":"Bryant Morocho, Sasha Lightfoot, Ponnandai Somasundar, Steve Kwon","doi":"10.1080/1750743X.2026.2688694","DOIUrl":"10.1080/1750743X.2026.2688694","url":null,"abstract":"Aims: Patients with stage II melanoma have multiple adjuvant therapy options in national guidelines. We evaluated management strategies to better define treatment in this heterogeneous population.Methods: Using the National Cancer Database (2010-2021), we identified patients with pathological stage IIA-IIC cutaneous melanoma who underwent surgical resection. Adjuvant treatment categories included no additional therapy (i.e. surgery only), immunotherapy, radiation, and immunotherapy plus radiation. Multivariable Cox proportional models evaluated overall survival by T-stage groups: T2b/T3a, T3b/T4a, and T4b and margin status (negative vs. positive).Results: 54,848 patients were identified (T2b/T3a n = 26,916; T3b/T4a n = 18,547; T4b n = 9,385). With negative margins, adjuvant therapy did not improve survival in T2b/T3a patients. Adjuvant immunotherapy in the negative margin cohort improved survival in T3b/T4a (HR 0.52, 95% CI: 0.44-0.62) and T4b (HR 0.54, 95% CI: 0.47-0.62) melanoma. Among patients with positive margins, no benefit was observed with adjuvant therapy of any modality among all T-stage group cohorts.Conclusion: The impact of adjuvant treatment on overall survival in stage II melanoma depended on T-stage and margin status. Patients with low-risk disease had no survival benefit, while those with high-risk melanoma, T3b/T4a and T4b, benefited from adjuvant immunotherapy after R0 resection.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"527-535"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13348935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148239185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrated pharmacological and Omega-3 therapy modulates immunometabolic pathways and neuro-ophthalmological outcomes in relapsing-remitting multiple sclerosis. 综合药物和Omega-3治疗调节复发缓解型多发性硬化症的免疫代谢途径和神经眼科结果。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-04-01 Epub Date: 2026-05-27 DOI: 10.1080/1750743X.2026.2676451

Tablo Ahmed Merza Mohammed, Teshk Nouri Shawis, Talar Ahmad Merza Mohammad, Maysoon Al-Haideri

{"title":"Integrated pharmacological and Omega-3 therapy modulates immunometabolic pathways and neuro-ophthalmological outcomes in relapsing-remitting multiple sclerosis.","authors":"Tablo Ahmed Merza Mohammed, Teshk Nouri Shawis, Talar Ahmad Merza Mohammad, Maysoon Al-Haideri","doi":"10.1080/1750743X.2026.2676451","DOIUrl":"10.1080/1750743X.2026.2676451","url":null,"abstract":"Aims: To investigate the immunometabolic and neuro-ophthalmological effects of combined Fingolimod, Metformin, Fluoxetine, and Omega-3 therapy in patients with relapsing-remitting multiple sclerosis (RRMS).Materials and methods: A total of 80 RRMS patients were analyzed. Peripheral blood mononuclear cells and serum samples were assessed for gene expression of apoptosis- and oxidative stress-related markers (BCL2, BAX, CASP3, NRF2, SOD2, AMPK2), cytokine levels (IL-6, TNF-α, IL-10, IFN-γ), and Th1/Th17 ratio. Optical coherence tomography (OCT) and visual evoked potentials (VEP) were used to evaluate neuro-ophthalmological outcomes.Results: Omega-3 supplementation was associated with reduced pro-inflammatory cytokines (IL-6, TNF-α) and increased IL-10 levels. It was also linked to higher expression of antioxidant-related genes (NRF2, SOD2, AMPK2) and modulation of T-cell balance, reflected by a reduced Th1/Th17 ratio. Integrated analysis showed distinct clustering of treatment groups, with Omega-3-associated profiles linked to anti-inflammatory and antioxidant signatures. These changes were correlated with improved RNFL thickness and VEP parameters.Conclusions: Omega-3 supplementation was associated with coordinated immunometabolic changes and improved neuro-ophthalmological indicators in RRMS patients, suggesting its potential as an adjunct to standard therapies.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"365-375"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148029904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regulatory T cells in kidney transplantation: mechanisms, therapeutic advances, and future directions. 调节性T细胞在肾移植中的作用：机制、治疗进展和未来方向。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-04-01 Epub Date: 2026-05-22 DOI: 10.1080/1750743X.2026.2676457

Yunting Shao, Shaochen Yu, Mengjie Zhang, Langlang Yang, Beibei Tian, Jian Lu

{"title":"Regulatory T cells in kidney transplantation: mechanisms, therapeutic advances, and future directions.","authors":"Yunting Shao, Shaochen Yu, Mengjie Zhang, Langlang Yang, Beibei Tian, Jian Lu","doi":"10.1080/1750743X.2026.2676457","DOIUrl":"10.1080/1750743X.2026.2676457","url":null,"abstract":"Regulatory T cells (Tregs) play a pivotal role as key modulators of immune tolerance in kidney transplantation, a critical therapeutic approach for end-stage renal disease. Despite advances in surgical techniques and immunosuppressive regimens, kidney transplantation continues to face significant challenges, including immune rejection and complications arising from long-term immunosuppression. In recent years, Tregs have garnered considerable attention due to their potential to promote graft immune tolerance, reduce the reliance on immunosuppressive drugs, and improve transplant outcomes. This review provides a comprehensive overview of the biological characteristics and immunoregulatory mechanisms of Tregs in the context of kidney transplantation. It highlights the clinical relevance of Tregs and summarizes the progress in Treg-based cellular therapies. Special emphasis is placed on emerging molecular pathways regulating Treg function, the role of immune metabolism, and innovative strategies utilizing nanocarrier systems to selectively expand Tregs. Furthermore, the review addresses current challenges in translating Treg research into clinical practice and outlines future research directions aimed at enhancing immune tolerance and graft survival. By synthesizing recent advances, this article aims to offer theoretical support for the clinical application of Treg-mediated immunomodulation in kidney transplantation.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"479-501"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CAR-iNKT cells for cancer therapy: a comprehensive review of engineering, mechanisms, and clinical progress. CAR-iNKT细胞用于癌症治疗：工程、机制和临床进展的综合综述。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-04-01 Epub Date: 2026-05-25 DOI: 10.1080/1750743X.2026.2674418

Ying Yang, Jiaqi Gu, Yujie Ding, Yuqin Li, Zhida Sun

{"title":"CAR-iNKT cells for cancer therapy: a comprehensive review of engineering, mechanisms, and clinical progress.","authors":"Ying Yang, Jiaqi Gu, Yujie Ding, Yuqin Li, Zhida Sun","doi":"10.1080/1750743X.2026.2674418","DOIUrl":"10.1080/1750743X.2026.2674418","url":null,"abstract":"Chimeric antigen receptor (CAR)-modified T cells, as a revolutionary cancer immunotherapy, have achieved remarkable success in hematologic malignancies. However, the therapy is hindered by severe toxicity, complex manufacturing, and suboptimal efficacy in solid tumors. Invariant natural killer T (iNKT) cells combine features of T cells and NK cells, bridging innate and adaptive immunity. Beyond direct cytotoxic functions, iNKT cells exert indirect antitumor effects through interactions with other immune cells while also modulating the tumor microenvironment (TME). Their exceptional TME infiltration capacity offers hope for solid tumor treatment. Leveraging their inherent major histocompatibility complex (MHC)-independent cytotoxicity, iNKT cells offer a viable strategy for developing \"off-the-shelf\" CAR cell products. Consequently, CAR-iNKT cell therapies developed by introducing CAR technology into iNKT cells demonstrate extraordinary potential as a next generation tumor immunotherapy. Despite being established and garnering attention, CAR-iNKT cell therapy remains nascent with numerous obstacles. This review comprehensively discusses CAR-iNKT cell therapy, from the fundamental biology of iNKT cells to the latest advances in engineering and clinical translation, offering new perspectives for its research, development, and application. A comprehensive literature search was conducted using [PubMed, Embase, and Web of Science] for articles published between [January 1900 and March 2026].","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"435-450"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148015382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tarlatamab in relapsed small-cell lung cancer: a DLL3-targeted bispecific T-cell engager. 塔拉他单抗治疗复发性小细胞肺癌：一种dll3靶向双特异性t细胞结合剂。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-04-01 Epub Date: 2026-05-04 DOI: 10.1080/1750743X.2026.2668210

Prodromos Koutoukoglou, Giannis Mountzios

{"title":"Tarlatamab in relapsed small-cell lung cancer: a DLL3-targeted bispecific T-cell engager.","authors":"Prodromos Koutoukoglou, Giannis Mountzios","doi":"10.1080/1750743X.2026.2668210","DOIUrl":"10.1080/1750743X.2026.2668210","url":null,"abstract":"Relapsed small cell lung cancer (SCLC) is widely considered as a difficult-to-treat disease with an adverse prognosis and scarce therapeutic options, especially in the case of platinum-resistance. Tarlatamab (IMDELLTRA™), a first-in-class, Delta-like ligand-3 (DLL3)-targeted bispecific T-cell engager (BiTE), works by creating a molecular bridge between DLL3 on tumor cells and CD3 on T-cells, leading to T-cell activation and Τ-cell-mediated tumor cell lysis. Tarlatamab demonstrated promising efficacy in early-phase trials at the cost of immune-mediated toxicities like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS and ICANS emerge primarily during the first two cycles of treatment, have low to moderate severity and are generally manageable with general supportive measures and specialized immunosuppressive treatment including corticosteroids and monoclonal antibodies like tocilizumab. Tarlatamab appears to be a promising choice for relapsed SCLC, based on the results of the Phase III DeLLphi-304 trial, which demonstrated a clinically and statistically meaningful improvement in overall survival (OS) with its use compared to approved second-line chemotherapy (ChT) options. Having been recently granted FDA approval for use in patients with SCLC who progressed on or after platinum-based ChT, tarlatamab is currently being evaluated in multiple settings of SCLC, including first-line and maintenance treatment.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"385-398"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0